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Primary immune thrombocytopenia (ITP) is a disorder caused by autoantibody-mediated platelet destruction 
and decreased platelet production. Rituximab, a B cell–depleting agent, has become the first-line treatment for 
ITP; however, patients with refractory disease usually require splenectomy. We identified antibody-secreting 
cells as the major splenic B cell population that is resistant to rituximab. The phenotype, antibody specificity, 
and gene expression profile of these cells were characterized and compared to those of antibody-secreting cells 
from untreated ITP spleens and from healthy tissues. Antiplatelet-specific plasma cells (PC) were detected in 
the spleens of patients with ITP up to 6 months after rituximab treatment, and the PC population displayed 
a long-lived program similar to the one of bone marrow PC, thus explaining for most of these patients the 
absence of response to rituximab and the response to splenectomy. When analyzed by multiplex PCR at the 
single-cell level, normal splenic PC showed a markedly different gene expression profile, with an intermediate 
signature, including genes characteristic of both long-lived PC and proliferating plasmablasts. Surprisingly, 
long-lived PC were not detected in untreated ITP spleens. These results suggest that the milieu generated by 
B cell depletion promotes the differentiation and settlement of long-lived PC in the spleen.
Introduction
T cell–dependent immune responses induce the generation of plas-
mablasts (PB) that migrate to the bone marrow, in which some of 
them reside for decades as Ig-secreting plasma cells (PC) (1–3). PC 
have also been described in normal human spleen. In the latter, they 
display a phenotype similar to that of bone marrow PC, with specific 
surface marker differences, but their precise life span has not been 
assessed (4). In addition to bone marrow and spleen, chronically 
inflamed tissues may also provide a surviving niche for long-lived 
PC, as shown in the lupus-prone NZBxNZW mouse model (5). The 
precise phenotype of PC in these different contexts is not estab-
lished and neither are the signals that drive these cells to reside in 
one particular niche and to acquire a long-lived program (6).
Primary immune thrombocytopenia (ITP) is an acquired bleed-
ing disorder mediated by pathogenic autoantibodies that enhance 
platelet destruction and limit their production (7, 8). The major tar-
get of these autoantibodies is the platelet membrane glycoprotein 
IIb-IIIa (GpIIbIIIa), but other glycoproteins may be involved (8). 
The spleen is not only the major site of platelet destruction but is 
also considered the main site of autoantibody production, thus 
seemingly containing all the players required to perpetuate the 
autoimmune reaction (9, 10). Accordingly, splenectomy has rep-
resented for decades the reference second-line treatment of severe 
chronic ITP, resulting in a durable platelet response in two-thirds 
of patients (11, 12).
More recently, anti-CD20–induced B cell depletion, which is 
used in several autoimmune diseases, has been increasingly used 
in persistent or chronic ITP prior to splenectomy. Around 40% of 
patients with ITP have an initial significant response to the anti-
CD20 (rituximab) treatment (13) and 20% have a long-lasting 
(5 years and more) response (14). Among the remaining patients, 
who do not respond or have a transient response to rituximab, 
60%–70% are cured by splenectomy (13–15). While reports agree 
on the efficient peripheral B cell depletion achieved by rituximab 
treatment, much less is known about B cell depletion in lymphoid 
tissues and the nature of the resistant pathogenic cells. Moreover, 
incomplete B cell elimination has been reported in the mouse, 
either through anti-mouse CD20 treatment (16, 17) or in a trans-
genic human CD20 mouse model treated with rituximab, thus 
questioning the extent of B cell depletion achieved in human lym-
phoid organs (18, 19). Possible immunomodulatory roles of rituxi-
mab through non–B cell compartments or through antibody-inde-
pendent mechanisms have also been proposed (20, 21).
In this study, we have taken advantage of the different thera-
peutic strategies and outcomes in patients with ITP to analyze the 
residual B cell populations present in rituximab-treated spleen 
and have identified a potentially pathogenic long-lived PC popu-
lation not targeted by rituximab. Transcriptomic analysis at the 
population and at the single-cell level, performed on splenic anti-
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body-secreting cells (ASCs) from HDs and from patients treated 
or not with rituximab, revealed striking differences between these 
different entities and challenged the accepted views of the envi-
ronmental conditions that permit the differentiation and resi-
dence of long-lived PC.
Results
Patients with ITP. Characteristics of 15 splenectomized patients 
with ITP, treated or not with rituximab, are presented in Supple-
mental Table 1 (supplemental material available online with this 
article; doi:10.1172/JCI65689DS1). Ten patients, with a median 
age of 40 years (range, 26–74 years), received 4 weekly infusions of 
375 mg/m2 rituximab. All were nonresponsive to rituximab, with 
platelet counts below 30 × 109/l or lower than the double of the 
baseline count in the month preceding splenectomy. They were 
splenectomized in the 3 to 6 months following the last rituximab 
infusion. Four of them received intravenous Igs (IvIg) in the 1–3 
weeks preceding the splenectomy. Seven out of ten presented with 
a complete response, with a follow-up of 7 to 24 months after 
splenectomy. Five patients with ITP were not treated with ritux-
imab and were splenectomized after a median ITP duration of 
24 months. Two of them received IvIg 2 weeks before splenectomy. 
All were responsive to the splenectomy, with a follow-up of 18 to 
30 months. The term “ITP” will be used hereafter for patients not 
treated with rituximab unless otherwise stated.
The spleen in ITP is the site of an active B cell response. We first inves-
tigated the presence of ASCs and germinal center (GC) B cells as 
hallmarks of an active immune response in the spleens of patients 
with ITP not treated with rituximab (Figure 1A and Supplemental 
Table 2). The major part of the ASC population in these patients 
expressed the Ki67 cell cycle marker and were HLA-DRhi, i.e., dis-
played a PB phenotype. Overall, PB were markedly increased in 
the spleens of these patients (Figure 1B). PC were slightly but not 
significantly increased compared with healthy donors (HDs) (Fig-
ure 1C). Similarly, the GC B cell population was also significantly 
expanded in these ITP spleens (Figure 1D). By confocal microscopy 
analysis, we found numerous GC structures within secondary folli-
cles in all ITP spleens examined (n = 3) (Figure 1E), whereas mainly 
primary follicles were observed in splenic samples from HDs 
(n = 3) (Figure 1F). PB were found in these ITP spleens (Figure 1, 
G and H) but were rarely detectable in HDs, with a wide distribu-
tion from the GC area to the red pulp. Numerous proliferating 
T cells were also observed in the patient with ITP and not in the HD 
(Figure 1, I and J). Altogether, our data indicate that the spleen is 
the site of an unusually active B cell response in patients with ITP.
Presence of anti-GpIIbIIIa IgG-producing cells in ITP spleens. We next 
investigated the ability of ASCs to produce autoantibodies in 
vitro. We used the previously described anti-GpIIbIIIa ELISPOT 
assay in order to quantify the fraction of autoreactive ASCs (9). 
In all but one spleen, we observed GpIIbIIIa-specific spots, rang-
ing from 0.5% to 1.2% of total IgG-secreting cells (Figure 1K and 
Supplemental Table 2). No anti-GpIIbIIIa IgG-secreting cells were 
observed in HDs (Figure 1L). After a 5-day culture of ITP spleens 
without stimulation, anti-GpIIbIIIa IgG-secreting cells were still 
observed with an increase of the size and the intensity of the spots 
(data not shown), reflecting the robustness of the response. All 
patients responded to the splenectomy, including the one showing 
a negative anti-GpIIbIIIa IgG ELISPOT.
Splenic residual B cells in patients with primary failure of rituximab are 
mainly PC and some of them are autoreactive. In order to study the 
residual B cells that survived the rituximab-suppressive action, we 
focused on rituximab-treated patients who did not respond and 
had been subsequently splenectomized within the 3–6 months 
after the last rituximab infusion, i.e. before the reemergence of 
newly formed B cells.
As extensively described, B cells were scarcely detectable in 
peripheral blood (<0.1% of CD45+ cells) (Table 1). We did not 
observe any dividing Ki67+ cells; all cells expressed the CD27 
marker, and more than 50% expressed IgA isotypes as previously 
described (data not shown) (22). By contrast, analysis of the 10 
spleens from rituximab-treated patients revealed that 0.5% of 
CD45+ mononuclear cells were B cells (Table 1). Further analy-
sis showed that these rituximab-resistant B lineage cells could 
be separated in two populations: memory B cells and PC (Figure 
2A). No dividing Ki67+ cells were observed. In all but one rituxi-
mab-treated patient, PC were the main residual population (Figure 
2B). As described for normal splenic samples (4), splenic PC from 
rituximab-treated patients (RTX-PC) did not express CD138 in 
contrast with bone marrow PC and did not downregulate CD19, as 
92%–98% of CD27+CD38hi cells were CD19+. RTX-PC were charac-
terized as CD38hiCD20–Ki67–HLA-DRloCD9+ cells (Figure 2A) and 
expressed splenic PC surface markers, such as CD86 and CD11a 
(ref. 4 and Supplemental Figure 1A). Patients who responded to 
splenectomy (7 out of 10) tended to have a higher number of PC in 
the spleen, as compared with nonresponders (Figure 2C), although 
this difference failed to reach significance due to the small number 
of patients in each category (P = 0.066)
We used the ELISPOT assay to determine whether some resid-
ual PC were autoreactive (Figure 2C). Residual PC expressed IgM, 
IgG, and IgA isotypes (Supplemental Figure 1B). We observed anti- 
GpIIbIIIa IgG-secreting cells in 7 out of 10 patients, with a fre-
quency ranging from 0.25% to 4%, but we failed to identify anti- 
GpIIbIIIa IgM- or IgA-secreting cells (Table 1). Six out of these 
seven patients presenting GpIIbIIIa-specific PC responded to the 
splenectomy, while specific spots were detectable in a patient who 
failed to respond (Figure 2, D and E).
Overall, these findings suggested that the failure of rituximab 
treatment could be explained in the majority of the patients by the 
presence of residual autoreactive anti-GpIIbIIIa PC in the spleen.
Residual PC in patients with primary failure of rituximab display a long-
lived genetic program. In patients with a primary failure of rituximab, 
the persisting splenic B cells are nondividing and contain minimal 
numbers of memory B cells, thus suggesting that the residual PC 
observed have been generated before the rituximab-induced deple-
tion and were thus long lived. To test this hypothesis, we performed 
a transcriptome analysis to compare the gene expression profiles 
of the various splenic ASC subsets from patients and controls. We 
sorted PC and PB from 3 HDs and 3 patients with ITP, using HLA-
DR expression to discriminate between them (gating strategy: 
Supplemental Figure 2), as well as PC from 4 rituximab-treated 
patients. We first focused on the 2 major subsets from patients, 
i.e., PB from patients with ITP (ITP-PB) and RTX-PC, which could 
be sorted to high purity due to their predominance in each cate-
gory of patients. We performed a supervised analysis and identi-
fied 609 differentially expressed genes (P < 0.05, > 4-fold change). 
The genes overexpressed in RTX-PC compared with those in ITP-
PB were antiapoptotic genes (BCL2, CFLAR, TNFAIP3, BIRC3); 
negative regulators of the cell cycle and notably several members 
of the family of Kruppel-like factors (KLF2, KLF6, KLF9, KLF15); 
transcription factors (FOS, JUN, JUNB, RORA); genes related to the 
research article
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Figure 1
Spleen in ITP is the site of an active B cell response producing anti-GpIIbIIIa–specific ASCs. (A) Flow cytometry analysis of splenic mononuclear 
cells labeled with antibodies to CD19, CD38, CD20, CD24, HLA-DR, and Ki67. After gating on CD19+ cells, ASCs were identified as CD20–, 
CD24–, CD38hi (blue); PB were identified as CD20–, CD24–, CD38hi, HLA-DR+, Ki67+ (red); and GC B cells were identified as CD20+, CD24–, 
CD38+, Ki67+ (green). (B–D) Numbers of splenic (B) PB, (C) PCs (identified as CD19+CD20–CD24–CD27+CD38hiKi67–), and (D) GC B cells in 
patients with ITP (n = 5) compared with HD (n = 8). (E–J) Analysis by confocal microscopy of spleen sections from a patient with ITP (ITP1) and 
a HD (17 years old) using anti-CD3, anti-CD20, anti-Ki67, and anti-IgL (anti-κ/λ light chains) antibodies. (E) Secondary follicles with proliferating 
GC B cells, (G, box enlarged in H) PB (CD20–, Ig κ/λ+, Ki67+), and (I, box enlarged in J) T cells (CD3+Ki67+) in patient with ITP and (F) primary 
follicles in HD. Scale bars: 100 μm (E–G and I); 5 μm (H and J). Data are representative of 3 ITP and HD samples. (K) ELISPOT quantification of 
anti-GpIIbIIIa IgG-secreting cells in 3 ITP (top) and 1 HD (bottom left) among total IgG-secreting cells (bottom middle), with KLH as antigen control 
(bottom right). (L) Frequency of anti-GPIIbIIIa IgG-secreting cells in patients with ITP (n = 5) compared with HD (n = 4). Two-tailed Mann-Whitney 
tests (***P < 0.001; *P = 0.044). Symbols indicate individual samples; horizontal bars represent mean values (± SEM).
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unfolded protein response (Dnaj, HSPB1, MAFF, ATF3); and genes 
encoding adhesion molecules or surface receptors (ICAM1, CD9, 
IL5R, IL6ST). On the other part, RTX-PC underexpressed, as com-
pared with ITP-PB, genes implicated in positive regulation of the 
cell cycle (BIRC5, CENPF, BUB1, BUB1B, ZWINT, MCM4, MKI67); 
genes encoding adhesion molecules (S1PR1, CD58); and activat-
ing molecules like TLRs (TRL10, TLR7) (Figure 3). Thus, RTX-PC 
expressed a specific genetic program consistent with a quiescent, 
long-lived phenotype.
The gene expression profile of PC from HDs differs from the one of RTX- 
PC. PB from patients with ITP and PC from rituximab-treated 
patients represent two opposites of the ASCs differentiation 
pathway. To position PC from HDs along this maturation scale, 
we compared the gene expression profile of PC from HDs to that 
of both ITP-PB and RTX-PC for the 609 discriminating genes 
described previously (Figure 3). For 267 of these genes, the expres-
sion was similar between RTX-PC and HD-PC, while for 99 of them, 
HD-PC expression was similar to that of ITP-PB (<2-fold change). 
Among the genes shared by HD- and RTX-PC were upregulated 
genes: transcription factors (JUN, JUNB, FOS), antiapoptotic genes 
(BIRC3), and adhesion molecules (CD9, ICAM1). Among genes with 
a similar low expression between HD-PC and ITP-PB were negative 
cell cycle factors (KLF4, KLF6, and KLF9). Forty-two genes were sig-
nificantly different (>2-fold change, P < 0.05) between HD-PC and 
both RTX-PC and ITP-PB, among which were BCL2 and cell cycle 
regulators/markers BUB1, CDC6, CENPF, MKI67, and MCM4. The 
gene expression profile of normal PC thus appears intermediate 
between RTX-PC and ITP-PB.
Single-cell gene expression analysis of HD-PC reveals an intermediate 
gene expression profile between RTX-PC and ITP-PB. The intermediate 
profile revealed by the HD-PC transcriptome analysis could be 
due either to a unique population with such an intermediate pro-
file or to a mixed population of long-lived PC and short-lived PB. 
To address this issue, we performed a single-cell gene expression 
analysis of splenic ASC subsets from patients and controls. We 
sorted PC from 2 HDs and 2 rituximab-treated patients as well as 
PB from 2 patients with ITP according to the HLA-DR expression 
criterion (see above). We selected 15 genes from the transcriptome 
analysis that discriminated PB from PC (BIRC5, BUB1, MKI67, 
ZWINT, CDC6, CCND2, CENPF, KLF6, KLF9, FOS, TNFAIP3, BIRC3, 
ATF3, CD9, and SOCS1 as well as B2M as control). Single-cell gene 
expression profiling was performed by multiplex RT-PCR using 
Fluidigm Dynamic Arrays, and data were processed by a principal 
component analysis (PCA). PCA reduces the complexity of a mul-
tivariate analysis to a few components (here 3), capturing a large 
part of the variance (depicted for each axis, see Figure 4A) through 
a linear combination of these variables. PCA of the single-cell 
gene expression profile revealed that RTX-PC and ITP-PB segre-
gated in 2 distinct populations, either normalized or not with the 
B2M housekeeping gene (Figure 4A and Supplemental Figure 3). 
The major fraction of HD-PC showed an intermediate profile 
that differed from that of RTX-PC and ITP-PB. A few cells clus-
tered with the RTX-PC or ITP-PB population. We then selected 8 
genes for further analysis: 4 cell cycle genes (BUB1, MKI67, ZWINT, 
CENPF, highly expressed in ITP-PB and at background level in 
RTX-PC) and 4 cell cycle regulators/antiapoptosis genes (KLF6, 
KLF9, TNFAIP3, ATF3, highly expressed in RTX-PC and expressed 
at a lower level in ITP-PB). Similar results were obtained for the 
PCA using this set of genes (Figure 4B). Based on their qualitative 
expression, we further classified each single cell with a “PB signa-
ture” (>1 cell cycle gene and ≤1 upregulated PC genes) or a “PC 
signature” (no cell cycle gene and >1 upregulated PC genes) or as 
“unclassified.” These differential criteria were selected to match 
the transcriptional characteristics of the genes in the 2 categories: 
an on/off expression for cell cycle genes and a low/high expression 
for PC-specific genes in ITP-PB vs. RTX-PC. According to these 
criteria, 84% of RTX-PC showed a “PC signature” and 75% of ITP-
PB showed a “PB signature.” In contrast, 75% of individual HD-PC 
were “unclassified,” with a “PC signature” identified for less than 
15% of them (Figure 4C). Thus, RTX-PC are a unique long-lived 
population from which the major part of HD-PC differ.
ITP-PC analyzed at the single-cell level do not display a long-lived program. 
To ask whether the presence of long-lived PC in rituximab-treated 
spleens could be contributed to by the autoimmune inflammatory 
environment, we analyzed PC from patients with ITP (not treated 
with rituximab) using the same single-cell multiplex PCR approach. 
PCA based on the expression profile of the 15 genes described previ-
ously indicated that, as for HD-PC, the PC present in patients with 
ITP showed an intermediate phenotype between long-lived PC and 
proliferating PB (Figure 4D). It seems therefore that the generation 
of the long-lived PC in spleens of rituximab-treated patients does 
not result from a previous inflammatory state.
Splenic ASC from patients with ITP display a specific genetic signature 
characterized by downregulation of SOCS3. To identify disease-spe-
Table 1
Number and repartition of residual blood and spleen B cells and spleen IgG and anti-GPIIbIIIa ASC in rituximab-treated patients
Patients Blood B cells/ Spleen B cells/ Absolute no. of  Spleen PC/ Absolute no. of IgG- Anti-GpIIbIIIa  
 CD45+ cellsA CD45+ cellsA spleen PC/106 cellsA CD19+ cellsA secreting cells/106 cellsB ASC/total IgGB
RTX 1 – 0.75% 3,781 67% 1,344 2.0%
RTX 2 – 0.54% 2,736 68% 1,200 3.0%
RTX 3 0.04% 0.47% 524 33% 600 4.0%
RTX 4 – 0.48% 1,330 55% 1,020 <0.05%
RTX 5 – 0.06% 378 92% 360 <0.1%
RTX 6 – 1.0% 5,053 97% 1,810 0.25%
RTX 7 0.03% 0.17% 834 82% 420 0.25%
RTX 8 – 0.20% 1,344 96% 688 0.88%
RTX 9 0.07% 0.51% 2,116 61% 1,601 0.84%
RTX 10 0.02% 0.19% 1,285 98% 1,224 <0.1%
ADetermined by FACS analysis. BDetermined by ELISPOT assay.
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cific genes, we extracted 158 probes that discriminated all patient 
subsets (ITP-PC [n = 3], ITP-PB [n = 3], and RTX-PC [n = 4]) from 
control subsets (HD-PC [n = 3] and PB [n = 2]) (>2-fold change, 
P < 0.01). The 12 most striking genes are shown in Figure 5A. 
ASC in HDs overexpressed SOCS3 as well as PTP4A3 (also known 
as PRL-3; involved in CXCL12-mediated migration of multiple 
myelomas, and, together with SOCS3, defining a multiple mye-
loma subtype) (23), in contrast with ASC from patients with 
ITP that expressed both genes minimally (a 50-fold difference). 
RT-PCR confirmed that low expression of SOCS3 is a hallmark 
of ITP ASC (Figure 5B). Contradictory data have been reported 
concerning the impact of SOCS3 on cell migration. Two groups 
described a negative feedback control of SOCS3 on the CXCR4 
signaling function (24, 25); on the other hand, Tarlinton and col-
leagues, while reporting a prolonged STAT3 signaling induced 
by IL-6 stimulation of SOCS3-deficient PC, observed no impact 
Figure 2
Autoreactive PC in patients with primary failure of rituximab. (A) 
Flow cytometry analysis of splenic mononuclear cells, labeled with 
anti-CD19, CD38, CD20, CD24, CD27, CD9, HLA-DR, and Ki67 
antibodies. All residual splenic B cells were CD19+CD27+ and 
included memory B cells (CD24+CD38–) and PC (CD24–CD38hi) 
(blue gate), further identified as CD20–HLA-DRloKi67–CD9+. (B) 
Percentage of PC per CD19 cells for each patient (mean, 74.9% 
[range, 33–98]). (C) Absolute numbers of spleen PC in rituxi-
mab-treated patients, segregated as responders and nonrespond-
ers to the splenectomy. Two-tailed Mann-Whitney test (P = 0.066). 
(D) Frequency of anti-GpIIbIIIa IgG-secreting cells in responders or 
nonresponders to the splenectomy. Two-tailed Mann-Whitney test 
(P = 0.64). (E) ELISPOT quantification of anti-GpIIbIIIa IgG-secret-
ing cells in 2 rituximab-treated patients among total IgG-secreting 
cells, with KLH as antigen control, estimated from 1 × 106 total 
spleen cells (RTX1 and RTX2) or 2 × 104 cell-sorted PC (RTX2, 
sorting of CD19+CD27+CD38hi cells). The dilution factor is indicated 
for IgG-positive spot detection. Symbols indicate individual sam-
ples; horizontal bars represent mean values (± SEM).
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of SOCS3 gene inactivation on CXCL12-induced migration of 
mouse B cells (26).
Interestingly, a higher expression of the CXCR4 gene was observed 
in ASC from patients with ITP compared with those from HD (Fig-
ure 5A), but cell surface expression of CXCR4 was similar between 
them (data not shown).
RTX-PC are nonmigratory cells that display a resident phenotype. In order 
to find out whether the overexpression of CXCR4 and downregula-
tion of SOCS3 and PRL-3 may have an impact on PC or PB migra-
tion toward CXCL12, we studied ASC migration by culturing total 
spleen cells with or without CXCL12. We observed that 30% of ASC 
migrated toward CXCL12 in ITP samples and 20% of ASC migrated 
toward CXCL12 in control samples, with a fraction of cells migrat-
ing without cytokines, as previously described (ref. 27 and Figure 
5C). The migratory population expressed high levels of HLA-DR at 
the surface, suggesting that it had a PB phenotype (data not shown). 
By contrast, RTX-PC were non migratory toward CXCL12, what-
ever the duration of cell culture (6, 12, 24 hours). RTX-PC did not 
express CXCR3, CD62L, or CCR10 (data not shown) but expressed 
CCR2, the receptor for CCL2 (see below), and the adhesion mole-
cules CD44, CD11a, and CD9 (Supplemental Figure 1A). RTX-PC 
are thus nonmigratory and display a resident phenotype.
ASC survival in ITP is increased, suggesting a role for the proinflam-
matory environment. We next wanted to assess whether the genetic 
signature observed could be correlated to the inflammatory ITP 
microenvironment. Both ASC from rituximab-treated patients 
and patients with ITP showed an increased survival compared 
with that of ASC from HD upon in vitro culture (P < 0.01) (Fig-
ure 6A). If the better persistence of ASC from rituximab-treated 
spleens is likely to reflect their intrinsic survival capacity in vitro, 
it might rather correspond, for ITP-PB, to a maintenance con-
tributed by proliferation. We next investigated whether specific 
cytokines could be involved and released in the culture medium. 
In a panel of 27 cytokines, we did not observe a bias for TH1 or 
TH2 cytokines, either in ITP or rituximab-treated patients (data 
not shown). By contrast, BAFF secretion was increased 2 fold in 
rituximab spleen supernatants compared with that in ITP spleens 
(P < 0.05) (Figure 6B); IL-6 was increased in 3 out of 4 ITP spleens 
compared with controls but not in rituximab samples (P < 0.05) 
(data not shown). There was no difference in APRIL secretion in 
rituximab and/or ITP spleen supernatants compared with those 
from HD (data not shown). CCL2 (also known as MCP-1) was 
significantly increased in both ITP and rituximab spleen cultures 
compared with that in HD cultures (Figure 6C), and its receptor, 
CCR2, was expressed at the RTX-PC surface. CCL2 has been shown 
to recruit monocytes, neutrophils, or basophils at inflammation 
sites. Accordingly, among other cell types tested, basophils num-
bers were increased in rituximab (P < 0.01) and in ITP (P < 0.05) 
Figure 3
Transcriptional analysis of ITP-PB, HD-PC, and RTX-PC 
reveals a specific long-lived gene expression profile for 
RTX-PC. Heat map clustering of genes selected from the 
supervised comparison of RTX-PC vs. ITP-PB (609 probes 
with a fold change >4 or <0.25 and P < 0.05), classified as 
transcription factors, positive regulation of cell cycle, nega-
tive regulation of cell cycle, antiapoptosis, unfolded protein 
response, and cell surface/cytokine receptors. Columns 
represent individual samples and rows represent specific 
gene probes, with upregulated genes in red and downregu-
lated genes in green (2-fold scale indicated). Complete data 
sets of the comparisons between RTX-PC and ITP-PB as 
well as between RTX-PC and HD-PC are included in Sup-
plemental Tables 3 and 4.
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spleens (Figure 6D). Nevertheless, addition of CCL2 to the in vitro 
culture did not modify ASC survival (data not shown). By contrast, 
addition of BAFF to the culture of total spleen cells from HDs 
increased the ASC survival by an average of 8 fold (P < 0.01) (Figure 
6E). We concluded that a proinflammatory environment, capable 
of increasing the ASC survival, may be driven by CCL2 and that 
the higher concentration of BAFF observed for rituximab spleen 
sample might selectively contribute to the survival of the resident 
RTX-PC population.
Discussion
Splenectomy performed in patients with ITP represents a 
unique opportunity to study the different partners involved in 
an autoimmune process. Here, we explored the short- and long-
lived ASC involved in different pathogenic settings as well as in 
normal conditions.
We found that, while normal adult spleen displays scarcely any 
GCs, patients with ITP showed an ongoing immune response with 
numerous active GCs (28), giving 
rise to some antiplatelet-specific 
ASC. This intense B cell response 
and considerable expansion of short-
lived PB in spleen is thus a hallmark 
of the disease. Rituximab-induced 
B cell depletion therapy is widely 
used in autoimmune diseases, and, 
accordingly, around 40% of patients 
with ITP respond to this therapy 
after 1 year (13) and 20% of them 
have a long-lasting response (14, 15). 
This rate of response underlines the 
efficacy of the rituximab treatment, 
being able to totally block the ongo-
ing production of ASC by proliferat-
ing GCs and memory B cells within 
lymphoid tissues (20).
We further analyzed the spleens 
of patients with ITP with a primary 
failure of rituximab treatment at 
a stage at which B lymphopoiesis 
had not restarted yet. In a config-
uration in which B cell depletion 
in the blood is almost complete, 
approximately 0.2%–1% of CD19+ 
B cells were shown to have resisted 
the rituximab-mediated depletion 
in the spleen. We identified, among 
the residual lymphoid cells, a major-
ity of PC that had survived in the 
total absence of GC B cells, divid-
ing memory B cells, and PB. A small 
percentage of these PC, which were 
mainly of the IgG isotype, secreted 
antiplatelet antibodies, thus pro-
viding an explanation for the failure 
of rituximab therapy. Accordingly, 
7 out of 10 patients responded to 
splenectomy, suggesting that such 
autoreactive cells were frequently 
restricted to the spleen.
We inferred that the PC observed in rituximab-treated spleens 
were made previous to the treatment, i.e., at least 3 to 6 months 
before splenectomy, and postulated that they could be long lived. 
The surface analysis of these splenic PC showed that they shared 
several markers with PC from normal bone marrow (HLA-DRlo 
CD9+Ki-67–). They differed from their bone marrow counterparts 
by expressing CD11a and CD86 and being negative for CD138. 
As such, they appeared similar to the PC previously described by 
Tangye and colleagues in normal human spleen (4, 27), with the 
additional information that they could be dated in this precise 
therapeutic setting. However, when rituximab-treated splenic 
PC were compared at the transcriptomic level with PC isolated 
from normal spleens and also with PB and PC extracted from the 
spleens of patients with ITP not treated with rituximab, the situa-
tion appeared more complex.
Transcriptomic analyses have so far focused mainly on bone 
marrow PC or on in vitro generated PB and PC in humans (29–31). 
By analyzing the short-lived PB in patients with ITP and the long-
Figure 4
The intermediate gene expression profile of HD-PC and ITP-PC compared with RTX-PC and ITP-PB is 
a cell-intrinsic characteristic. Multiplex single-cell PCR was performed with the Fluidigm Dynamic Array 
on RTX-PC, ITP-PB and HD-PC using 15 genes showing differential expression between RTX-PC 
and ITP-PB (BIRC5, BUB1, MKI67, ZWINT, CDC6, CCND2, CENPF, KLF6, KLF9, FOS, TNFAIP3, 
BIRC3, ATF3, CD9, SOCS1). Cells expressing less than 2 genes were excluded from the final analysis. 
(A) 3D representation of the PCA of 504 single cells analyzed according to these 15 genes. Each dot 
represents a single cell: red, ITP-PB; yellow, RTX-PC; blue, HD-PC. The Ct value was normalized for 
each cell with B2M. (B) 3D PCA view of the same samples according to the expression of 8 genes: 
4 “PB genes” (cell cycle genes: BUB1, MKI67, ZWINT, CENPF), highly expressed in ITP-PB and at 
background level in RTX-PC, and 4 “PC genes” (KLF6, KLF9, TNFAIP3, ATF3), highly expressed in 
RTX-PC and expressed at a low level in ITP-PB. (C) A simplified classification of each cell analyzed 
using the 8 genes defined above to classify cells with a “PB signature” (>1 cell cycle gene and ≤1 PC 
genes) or a “PC signature” (no cell cycle gene and >1 PC genes) or as “unclassified.” (D) 3D PCA view 
of ITP-PC together with ITP-PB and RTX-PC analyzed according to the 15 genes defined above. 
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lived PC in rituximab-treated patients, we provided for the first 
time in humans, the comparison of the two opposite sides of the 
in vivo ASC genetic program. Splenic RTX-PC presented a bona 
fide long-lived program very similar to the one of bone marrow 
PC, characterized by a strong expression of antiapoptotic factors 
and of negative regulators of the cell cycle, including multiple 
members of the Krüppel-like factor family, of the AP-1 family, 
and of genes involved in the unfolded protein response (30–34). 
In contrast, PB overexpressed positive regulators or markers of 
the cell cycle.
When compared with RTX-PC, surprisingly, normal splenic PC 
displayed an intermediate profile with the expression of some 
antiapoptotic genes shared with long-lived PC and some cell cycle 
genes expressed by PB. To unravel whether normal PC were a mix-
ture of several populations or represented a distinct PC differen-
tiation stage, their transcriptomic profile was analyzed at the sin-
gle-cell level and compared with single PC and PB isolated from 
patients with ITP, treated or not with rituximab. Based on a small 
group of genes differentially expressed by PB or long-lived PC, 
this analysis showed that most of the normal splenic PC showed a 
genetic profile with a mixed PC and PB signature. Interestingly, PC 
from patients with ITP not treated with rituximab also displayed, 
at the single-cell level, an intermediate phenotype with the expres-
sion of long-lived PC and PB genes, suggesting that the inflamma-
tory environment of the ITP spleen does not favor the formation 
of PC with a long-lived phenotype.
The gene expression profiles described here are intriguing 
because they suggest at first that normal splenic PC may display 
some characteristics of a long-lived program, while keeping at the 
same time the capacity to enter into proliferation. Such cellular 
divisions have never been described for PC, but they may occur at a 
very low rate in defined homeostatic situations. Whether these PC 
that have kept some PB characteristics can still migrate to other 
lymphoid sites also remains an open question (29). These data 
also suggest that the human spleen in an autoimmune inflamma-
tory environment is not a niche for long-lived PC. An alternative 
explanation for the absence of long-lived splenic PC in the ITP set-
ting could be the ongoing production of PB and PC that would 
prevent their local accumulation. Our observation seems to differ 
from the one in lupus-prone NZBxNZW mice, in which splenic 
PC, which are in large excess as compared with control animals 
(5), have differentiated into long-lived PC in the absence of any 
B cell–depleting therapy. In the human autoimmune setting that 
we described, which may be quite different from the previous 
mouse model in which there is a genetic predisposition for an 
ongoing autoimmune reaction, the total number of PC is in fact 
within the same range in ITP and rituximab-treated spleens. This 
result argues against the survival of a few PC present in ITP spleen 
that would already possess the long-lived characteristics but rather 
suggests that the rituximab-treated human spleen in ITP provides 
a unique environment in which rituximab-resistant ASC can dif-
ferentiate into bona fide long-lived PC. Interestingly, B cell deple-
tion in healthy mice, either by irradiation (2) or by anti–B cell anti-
body treatment (35), also triggered the establishment of splenic 
long-lived PC, suggesting that it is possibly the absence of B cells 
and the resulting excess of accessory cells or cytokines necessary 
for PC survival, such as BAFF (see below), which may be respon-
sible for this phenomenon. These results may bear some clinical 
relevance, since they would suggest that treatment with rituximab 
may paradoxically induce in certain situations the differentiation 
of autoimmune PC into long-lived resident cells.
Stromal cells, eosinophils, and megakaryocytes secreting 
CXCL12, IL-6, and APRIL have been shown to interact with 
long-lived PC in bone marrow, and IL-6–secreting basophils and 
stromal cells have been shown to interact with PC in the spleen 
(27, 36–41). A specific inflammatory milieu could promote the 
residence of long-lived PC in rituximab-treated patients, since 
RTX-PC survived better than control ones upon in vitro incuba-
tion of total splenic cells. A multiplex cytokine analysis of these 
culture supernatants revealed an increase in secretion of CCL2, a 
chemokine with the potential to attract monocytes, neutrophils, 
and basophils (42, 43), an increase that was, however, common 
to the ITP and rituximab treatment conditions. Accordingly, 
basophil numbers were markedly enhanced in both cases. The 
Figure 5
Splenic ASC from patients with ITP display a specific genetic signature characterized by downregulation of SOCS3. (A) Selected genes show-
ing significant difference in expression between ASC from disease samples (ITP-PC, RTX-PC, ITP-PB) compared with ASC from HDs (HD-PB 
and HD-PC) (n = 158; fold change, >2 or <0.5; P < 0.01). Gene expression profiling was performed using Affymetrix U133 Plus 2.0 microarrays 
after cDNA preamplification. (B) Enhanced expression of suppressor of cytokine signaling 3 (SOCS3) in HD compared with samples of patients 
with ITP. SOCS3 expression was determined by real-time quantitative RT-PCR, with values normalized for B2M expression. Mann-Whitney test 
(*P < 0.05). (C) Migration of ASC toward CXCL12 in a transwell migration assay. 1 × 106 cells from ITP (n = 2), HD (n = 2), and rituximab (n = 2) 
splenic samples were cultured overnight in triplicates. The ASC populations were gated as CD3–CD19+CD27+CD38hi cells, and the proportion of 
migrating cells was estimated compared with the total number of cells. Mean ± SEM.
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main differences in cytokine secretion concerned IL-6 and BAFF, 
whose secretion was increased in ITP and rituximab-treated spleen 
supernatants, respectively. The increase in BAFF secretion could 
be a direct consequence of B cell depletion (44, 45) and might con-
stitute a key factor, allowing, together with other players, for the 
settlement of long-lived PC in the rituximab-treated spleen.
Many questions remain unanswered in antibody-mediated auto-
immune diseases such as ITP. What drives the intense GC reaction 
and PB production in the ITP spleen, also described in many other 
target organs of human autoimmune diseases, since only a small 
percentage of the PC produced seem to secrete autoantibodies? 
As recently highlighted, inflammatory B cells producing cytokines 
such as IL-6 may promote this local B cell activation, but the mech-
anism of tolerance breakdown remains unknown (46). Finally, a 
straight forward proposition coming out of these results is that 
ITP may be caused either by autoimmune CD20+ memory B cells 
and the short-lived PB and PC they produce (response to rituxi-
mab) or by long-lived CD20– pathogenic PC present in the spleen 
(response to splenectomy after rituximab failure) or in other lym-
phoid niches (47) (failure of both treatments). One future thera-
peutic goal in ITP could be, according to our results, to modulate 
the splenic microenvironment, such as with an anti-BAFF therapy 
associated with rituximab, in order to prevent the generation of 
splenic long-lived PC.
Methods
Patients with ITP and healthy 
controls
Patients with ITP. All patients 
included fulfilled the following cri-
teria: age, ≥18 years; ITP diagnosis 
according to the American Society 
Hematology guidelines. Exclu-
sion criteria were as follows: other 
disease(s) associated with ITP 
(immunodeficiency, hepatitis C 
virus infection, lymphoprolifer-
ative disorders, thyroid or liver 
disease, and definite systemic 
lupus erythematosus [≥4 Ameri-
can Rheumatism Association cri-
teria]). Evan’s syndrome has also 
been excluded. Response rate to 
splenectomy was defined accord-
ing to the international criteria: 
complete response (defined as a 
platelet count >100 × 109/l); pri-
mary platelet response (defined 
as a platelet count ≥50 × 109/l, 
with at least the doubling of the 
baseline value without any rescue 
intervention during the preceding 
8 weeks); and no response (defined 
as a platelet count <50 × 109/l). 
Blood samples were obtained for 
4 RTX-treated patients at the time 
of splenectomy.
Controls. The characteristics of 
the subjects, including age and sex, 
at the time of sample collection, are 
detailed in Supplemental Table 2. All died from stroke. None presented with 
lymphoma or known autoimmune disease.
Confocal microscopy analysis of human spleens 
Immediately after splenectomy, pieces of splenic tissue were excised and 
embedded in OCT (Sakura), snap frozen in liquid nitrogen, and stored at 
–80°C. Cryosections (7–9 μm) were cut, fixed in cold (–20°C) acetone for 
10 minutes, rehydrated in wash buffer (TBS, pH 7.6), and incubated in 
blocking buffer (0.5% BSA and 10% goat serum in PBS) for 30 minutes at 
room temperature. Sections were then incubated for 60 minutes at room 
temperature, with the indicated primary antibodies in the blocking buf-
fer solution (see Supplemental Table 3 for a complete list of antibodies). 
Incubations without primary antibodies were used as control. Sections 
were washed 3–4 times and incubated with the secondary antibody as 
indicated (30 minutes at room temperature). Sections were washed and 
mounted in Fluoromont-G (Southern Biotech). Images were acquired 
by confocal microscopy with a LSM 700 (Zeiss). Fluorescence of single 
channels was measured, and control reference was systematically done. 
Pictures were taken with an objective ×40. Images were analyzed and pro-
cessed with ImageJ version 1.46.
Flow cytometry and cell sorting
Antibodies used are listed in Supplemental Table 3. Intracellular staining 
was performed after cell fixation and permeabilization with the BD Cyto-
Figure 6
ASC in ITP display a prolonged in vitro survival within a specific cytokinic and cellular microenvironment. 
(A) ASC survival after 5-day culture. Survival was estimated by the fraction of input ASC detectable after 
5-day culture of 5 × 105 spleen cells in triplicate, estimated by an anti-Ig ELISPOT (mean survival, RTX: 
26.4% ± 3.7%; ITP: 32% ± 9.5%; HD: 9.3% ± 1.6%). (B) BAFF concentration in spleen supernatants after 
5-day culture. BAFF concentration was estimated by ELISA in culture medium of 105 spleen cells cultured 
in triplicates for 5 days (mean BAFF secretion, RTX: 33.6 ± 6.2 pg/ml; ITP: 7.2 ± 1.2 pg/ml; HD: 20.2 ± 1 
pg/ml). (C) CCL2 concentration in spleen supernatants after 5-day culture. CCL2 concentration was esti-
mated as part of a multiplex 27-cytokine assay in spleen supernatants of 105 cells cultured in triplicate for 
5 days (mean CCL2 secretion, RTX: 11,410 ± 228 pg/ml; ITP: 11,410 ± 1,236 pg/ml; HD: 3,233 ± 1,927 pg/
ml). (D) Number of basophils in ITP and rituximab spleens. Spleen basophils were estimated by flow cytom-
etry as numbers of HLA-DR–CD123+FcεRIhi cells per 105 cells (mean basophil numbers, RTX: 1,162 ± 79.8; 
ITP: 591± 178.4; HD: 201 ± 64.5). (E) ASC survival from HD spleens after culture with or without BAFF (100 
ng/ml). Survival was estimated as in A. The values obtained with or without BAFF for each sample are 
connected by a straight line (median fold increased survival with BAFF: 8.3 [3.2–23]). Significant differences 
estimated by Mann-Whitney and paired t test (**P < 0.01, *P < 0.05). Symbols indicate individual samples; 
horizontal bars represent mean values (± SEM).
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Technologies), fragmented, and labeled with biotin using the Encore Biotin 
Module (NuGEN Technologies), as recommended by the manufacturer. 
Expression analysis was performed using GeneChip Human U133 Plus 2.0 
Arrays (Affymetrix). Gene expression levels were calculated using GCRMA, 
and flags were computed using MAS5 within R. To limit potentially biased 
measurements (background or saturating), all probes whose flags were absent 
or marginal were flagged as 0, whereas those present were flagged as 1. The 
group comparisons were done using a Student’s t test. To estimate the false 
discovery rate, we filtered the resulting P values at 0.05 (or 0.01 in certain 
cases) and considered data with 2- or 4-fold changes between samples. Data 
were subsequently compared to the gene ontology database (http://www.
geneontology.org/). Complete data sets have been deposited in EMBL-EBI 
database (http://www.ebi.ac.uk/arrayexpress/; accession no. E-MEXP-3711).
Single-cell gene expression analysis
Single splenic PC from 2 HDs and 2 rituximab-treated patients and single 
PB and PC from 2 patients with ITP were isolated by cell sorting. Cells 
were sorted in 5 μl of buffer containing the RT-PCR reagents and the pre-
amplification primers (CellsDirect One-Step qRT-PCR mix, SuperScriptIII 
RT/Platinum TaqMix 2%, and TaqMan primers (×0.005) [Applied Biosys-
tems]). A list of primers is available in Supplemental Table 4. After reverse 
transcription and gene-specific preamplification, cDNAs were diluted 
5 times and kept frozen at –20°C. 10× primer solutions were prepared with 
2× Assay Loading Reagent (Fluidigm). cDNA were mixed with TaqMan 
Universal PCR Master Mix 2× (Applied Biosystems) and ×20 GE Sample 
Loading Reagent (Fluidigm). Assay mix and cDNA mix were then trans-
ferred in a 48.48 Dynamic Array primed chip, and real-time PCR was run 
according to the Fluidigm protocol. 100-cell and no-cell wells were used 
as positive and negative control, respectively. Data were analyzed using 
Fluidigm Real-Time PCR analysis software. HLA-DRB1, CD38, CD27, and 
CD3 genes were used as control genes. To limit potentially biased mea-
surements, cells with less than 2 expressed genes among the 15 selected 
diagnostic genes were excluded from the analysis. PCA was performed with 
GeneSpring analysis software. PCA was performed with and without nor-
malization of the Ct value for each gene with the B2M housekeeping gene.
Statistics
Statistical comparisons were made with the nonparametric Mann-Whitney 
test, and the Wilcoxon signed-rank test was used for paired samples using 
GraphPad Prism. A P value of ≤ 0.05 was considered as significant.
Study approval
The study was approved by the Agence de la Biomédecine and the Comité 
de Protection des Personnes (CPP) Ile de France-II for controls and by the 
CPP Ile de France-IX for patients with ITP. This study was conducted in 
accordance with the Helsinki Declaration, with informed consent obtained 
from each patient with ITP for collecting splenic samples.
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(PB) fractions in HDs and patients with ITP and CD3–CD19+CD27+CD38hi 
cell fractions in patients treated with anti-CD20. The cell purity after sort-
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ELISPOT assays
Anti-GpIIbIIIa IgG PC detection. Multiscreen 96-well filter plates (MSIPS4510; 
Millipore) were coated by incubation overnight at 4°C with 2.5 μg/ml key-
hole limpet hemocyanin (KLH), 10 μg/ml goat anti-human Ig polyvalent 
antibody (Invitrogen), or 30 μg/ml purified GpIIbIIIa (Kordia Science) and 
coated in PBS/CaCl2 0.05%. 1 × 106 cells were serially diluted in culture 
medium in triplicate before transfer to ELISPOT plates and cultured 4–6 
hours in complete culture medium at 37°C under an atmosphere contain-
ing 5% CO2. The ELISPOT was revealed with biotinylated goat anti-human 
IgG Fc (Invitrogen), followed by HRP-conjugated avidin (Vector Laborato-
ries) and developed using 3-amino-9-ethylcarbazole (Sigma-Aldrich). Spots 
were counted in wells showing more than 3 specific spots in an ELISPOT 
reader with the AID software (version 3.5; AutoImmun Diagnostika). 
When detected, IgG-secreting anti-GpIIbIIIa spot numbers were reported 
to IgG-positive spots. When no specific spot was detectable, a value “less 
than x” was assigned, with x corresponding to the frequency obtained if 
1 GpIIbIIIa spot were detected at the lowest dilution.
PC survival. After spleen cultures, IgG-, IgA-, and IgM-secreting cells were 
assessed to estimate ASC survival. Briefly, 0.5 × 106 to 1 × 106 cells were 
either serially diluted in 96-well filter plates and cultured for 6 hours or were 
cultured 5 days in 1 ml complete culture medium at 37°C in triplicate in a 
24-well plate before serial dilutions. The ELISPOT was revealed as described 
above. The ratio of ASC detected between day 5 and day 0 was used as an 
estimate of in vitro ASC survival. In some experiments, human recombinant 
BAFF (Peprotech, 100 ng/ml) was added in the culture from splenic HD.
Cytokine assays
Culture supernatants of 1 × 106 spleen cells per ml plated in 24-well plates 
were collected at day 5. Quantitative determination of secreted cytokines 
was performed with the Bio-Rad human cytokine 27-plex assay, carried out 
according to the manufacturer’s instructions. The human TNSF13B/BAFF, 
CXCL12 (Quantikine, RD systems), and APRIL (USCNK) immunoassays 
were carried out according to the manufacturer’s instructions.
Chemotaxis assay
Chemotaxis assays were performed using transwell plates (Corning). CXCL12 
(Peprotech) was added to wells of a 24-well plate at 100 ng/ml. 1 × 106 spleen 
cells were cultured overnight in the upper well. The migrating ASC popu-
lation was estimated by FACS as CD3–CD19+CD27+CD38hi cells present in 
the lower well. The chemotaxic index was calculated as the number of cells 
migrating in the presence of chemokines versus the total number of cells.
Gene expression profiling
RNA was isolated from sort-purified PC (CD19+CD20–CD27+CD38hi 
HLA-DRlo) and PB (CD19+CD20–CD27+CD38hiHLA-DRlo) from 3 spleens 
of HDs and of patients with ITP (ITP1, ITP2, ITP3). PC (CD3–CD19+CD27+ 
CD38hi) were isolated from 4 spleens of rituximab-treated patients (RTX1, 
RTX2, RTX6, RTX8). Total RNA was isolated using the RNeasy Micro Kit 
(QIAGEN). RNA quality and concentration were assessed using RNA 6000 
Pico LabChips with a 2100 Bioanalyzer (Agilent Technologies). Total RNA 
(10 ng) was preamplified by Ribo-SPIA (Ribo–single primer isothermal 
amplification) RNA Amplification using the Ovation Pico WTA Kit (NuGEN 
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